FDA Adverse Event Injury Summary report: N

ZILVER VENA VENOUS SELF EXPANDING STENT

MDR report key: 15864358 · Received November 25, 2022

Report

Report Number
3001845648-2022-00804
Event Type
Injury
Date Received
November 25, 2022
Date of Event
October 26, 2022
Report Date
January 17, 2023
Manufacturer
COOK IRELAND LTD
Product Code
QAN
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER
Health Professional
N

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION IS STILL PENDING, A FOLLOW UP MDR WILL BE SUBMITTED TO INCLUDE THE INVESTIGATION CONCLUSIONS. PMA/510(K) #: P200023. COMMON NAME - QAN.

Additional Manufacturer Narrative · 0

COMMON NAME: (B)(6). PMA/510(K) #: P200023. DEVICE EVALUATION: THE DEVICE EVALUATION COULD NOT BE COMPLETED AS THE DEVICE OR PHOTOGRAPHIC EVIDENCE OF THE DEVICE WAS NOT RETURNED FOR EVALUATION. WITH THE INFORMATION PROVIDED, A DOCUMENT-BASED INVESTIGATION WAS CONDUCTED. THIS FILE IS RELATED TO PR (B)(4). LAB EVALUATION ¿ N/A. DOCUMENT REVIEW: PRIOR TO DISTRIBUTION ALL ZILVER VENA DEVICES ARE SUBJECTED TO A VISUAL INSPECTION AND FUNCTIONAL INSPECTION TO ENSURE DEVICE INTEGRITY. IT SHOULD BE NOTED THAT THE INSTRUCTIONS FOR USE (IFU0047) LISTS RESTENOSIS OR THROMBOSIS OF THE STENTED VEIN AS A POTENTIAL ADVERSE EVENT. THERE IS NO EVIDENCE TO SUGGEST THE USER DID NOT FOLLOW THE IFU. THERE IS NO EVIDENCE TO SUGGEST THAT THE CUSTOMER DID NOT FOLLOW THE LABEL. IMAGE REVIEW: AN IMAGE WAS NOT RETURNED FOR EVALUATION. ROOT CAUSE REVIEW: A DEFINITIVE ROOT CAUSE COULD NOT BE DETERMINED HOWEVER A POSSIBLE ROOT CAUSE CAN BE ATTRIBUTED TO THE PROCEDURE. ACCORDING TO THE LITERATURE PAPER, THE EVENT WAS ¿NOT RELATED TO ZILVER VENA, IT SHOULD ALSO BE NOTED THAT THE IFU LISTS RESTENOSIS OR THROMBOSIS (OCCLUSION) OF THE STENTED VEIN AS A POTENTIAL ADVERSE EVENT. SUMMARY: THE COMPLAINT IS CONFIRMED BASED ON CUSTOMER TESTIMONY. THE COMPLAINT WAS RAISED FROM THE CLINICAL STUDY ¿EVALUATION OF THE ZILVER VENA VENOUS STENT IN SPAIN ¿ DR. (B)(6) (PHYSICIAN ¿ DRIVEN STUDY ¿ AMBISPECTIVE REVIEW OF PATIENTS UNDERGOING PROXIMAL VENOUS STENT PLACEMENT). ACCORDING TO THE LITERATURE PAPER, 01 PATIENT EXPERIENCED STENT OCCLUSION SYMPTOMS WHICH RESULTED IN AN ENDOVASCULAR TREATMENT AND ADDITIONAL STENT PLACEMENT 22 DAYS POST-PROCEDURE. AS PER MEDICAL ADVISOR INPUT ¿REQUIRE INTERVENTION/ADDITIONAL PROCEDURES TO PREVENT PERMANENT IMPAIRMENT/DAMAGE¿. COMPLAINTS OF THIS NATURE WILL CONTINUE TO BE MONITORED FOR POTENTIAL EMERGING TRENDS.

Description of Event or Problem · 0

THE MAIN OBJECTIVE OF THIS AMBISPECTIVE, SINGLE CENTER, NONRANDOMIZED, SINGLE-ARM, PHYSICIAN-DRIVEN STUDY WAS TO EVALUATE THE PATENCY OF THE ZILVER® VENA¿ VENOUS SELF-EXPANDING STENT (I.E., THE ZILVER® VENA¿ VENOUS STENT) IN PATIENTS UNDERGOING VENOUS STENTING. THIS REPORT FOCUSES ON DATA FROM THE 239 PATIENTS THAT HAD A ZILVER VENA VENOUS STENT PLACED AT AN INDEX PROCEDURE. PATIENT 18 HAD RESTENOSIS/RECURRENCE OF SYMPTOMS AND REQUIRED STENT REPLACEMENT. PATIENT 18 HAD A STENT OCCLUSION, WHICH RESULTED IN AN ENDOVASCULAR TREATMENT AND ADDITIONAL STENT PLACEMENT 22 DAYS POST-PROCEDURE AS REPORTED IN TABLE 3.9.1-2. 26 DAYS POST-PROCEDURE NEW THROMBOSIS WAS NOTED PARTIALLY IN THE ILIAC SEGMENT AND ALL OF THE FEMORAL VEIN STENT. THIS WAS REPORTED ALL AS ONE EVENT BY THE PHYSICIAN. RESTENOSIS/RECURRENCE OF THROMBSIS SYMPTOMS: TIME TO DIAGNOSIS 26 DAYS. RELATED TO THE PROCEDURE; RESIDUAL THROMBOSIS AFTER LYSIS OF INFLOW. IMAGING MODALITY TO DIAGNOSE EVENT ULTRSOUND. NO NEW INTERVENTION HAS BEEN PERFORMED TO TREAT THE THROMBUS NOTED 26 DAYS POST-PROCEDURE. PATIENT OUTCOME: REQUIRED IMAGING, ENDOVASCULAR TREATMENT AND STENT REPLACEMENT.

Description of Event or Problem · 0

SUPPLEMENTAL REPORT IS BEING SUBMITTED DUE TO THE COMPLETION OF THE INVESTIGATION ON 18-JAN-2023.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2686825 ZILVER VENA VENOUS SELF EXPANDING STENT Stent, iliac vein QAN COOK IRELAND LTD UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 Unknown Required Intervention